A new therapeutic target for metastatic and resistant prostate cancers

 5 months ago       61 Views

A new combined therapy to fight the most aggressive and resistant prostate cancers.

This is one of the conclusions reached by Prostate Cancer researchers from the Bellvitge Biomedical Research Institute (IDIBELL), led by Dr. Álvaro Aytés.

The team, which has just published its latest results in Nature Communications, also includes researchers from the Catalan Institute of Oncology, Columbia University in New York and the University of Bern in Switzerland.

Specifically, researchers showed that these tumors generate increasing levels of the NSD2 protein during tumor progression and acquisition of resistance to therapies.

For these reasons, NSD2 represents an emerging therapeutic target against prostate cancer.

This process of chemical modification of DNA, or epigenetics, is often associated with the control of gene expression.

One of the main hypotheses of the researchers behind this study is that the activation of these genes - caused by NSD2 - is responsible for the development of resistance to the chemotherapeutic treatments usually administered to prostate cancer patients.

In fact, the study has shown that the pharmacological inhibition of NSD2 results in an increase in the survival of the experimental model, a decrease in metastasis and a reduction in the size of the tumors.

Thanks to these results, researchers conclude that the inhibition of NSD2 could lead to re-sensitization of prostate tumors that show resistance to the usual antiandrogenic treatments.

are not responsible for the accuracy of news releases posted to EurekAlert!

Author: @DailyCupofYoga

Source: eurekalert.org

Join the community!

You must be a member of healtheo360 in order to view this group

Register with Email Address

Already a member? Click here to login

healtheo360 believes strongly in user privacy.